Activation of the Wnt/β-catenin signaling pathway is implicated in thyroid tumorigenesis, and up to 90% of papillary thyroid cancer (PTC) demonstrate aberrant expression of β-catenin. Nonsteroidal antiinflammatory drugs reverse aberrant β-catenin expression and localization in colon cancer. In this study, we tested the hypothesis that the nonsteroidal antiinflammatory drug sulindac would reverse aberrant β-catenin activity in thyroid cancer cells.
Methods:
β-catenin protein levels were determined in thyroidectomy specimens from six consecutive patients and in three different thyroid cancer cells lines (8505-C, KTC-1, and TPC-1) by immunoblotting. Cells of 8505-C and KTC-1 harbor the BRAFV600E mutation, and TPC-1 has the RET/PTC rearrangement. All cell lines were treated with sulindac (100 μM for up to 72 hours). Protein levels of c-myc and cyclin D1 were detected by immunoblotting, and β-catenin localization was determined by immunocytochemistry in the PTC cell lines. PCCL3 rat thyroid cells that conditionally overexpress either BRAFV600E or RET/PTC were also treated with sulindac.
Results:
All PTC specimens and cell lines expressed high levels of β-catenin protein and displayed aberrant nuclear and cytoplasmic localization of β-catenin. Exposure to sulindac for 48 hours reduced β-catenin expression in 8505-C and KTC-1 cells, but not in TPC-1 cells. Further, sulindac treatment reduced c-myc and cyclin D1 levels in 8505-C and KTC-1 cells, but had no effect in TPC-1 cells. Immunocytochemistry demonstrated that sulindac treatment redistributed β-catenin from the nucleus to the membrane in 8505-C and KTC-1 cells. However, sulindac did not affect β-catenin localization in TPC-1 cells. Finally, sulindac was effective in decreasing β-catenin expression and cellular proliferation in BRAFV600E-overexpressing cells, but not in RET/PTC3-overexpressing cells.
Conclusions:
Taken together, our findings demonstrate that sulindac treatment reverses β-catenin activity in 8505-C and KTC-1 cell lines with the BRAFV600E, but not in TPC-1 cells with the RET/PTC mutation. Future studies should investigate the potential for β-catenin-directed therapy for patients with advanced thyroid cancers.
Get full access to this article
View all access options for this article.
References
1.
JemalA, SiegelR, WardE, HaoY, XuJ, MurrayT, ThunMJ. 2008. Cancer statistics. CA Cancer J Clin, 58:71–96.
2.
SantoroM, MelilloRM, CarlomagnoF, FuscoA, VecchioG. 2002. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci, 963:116–121.
3.
XuX, QuirosRM, GattusoP, AinKB, PrinzRA. 2003. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 63:4561–4567.
4.
KimuraET, NikiforovaMN, ZhuZ, KnaufJA, NikiforovYE, FaginJA. 2003. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63:1454–1457.
SoaresP, TroviscoV, RochaAS, LimaJ, CastroP, PretoA, MaximoV, BotelhoT, SerucaR, Sobrinho-SimoesM. 2003. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22:4578–4580.
7.
FrattiniM, FerrarioC, BressanP, BalestraD, De CeccoL, MondelliniP, BongarzoneI, ColliniP, GariboldiM, PilottiS, PierottiMA, GrecoA. 2004. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 23:7436–7440.
8.
AbboshPH, NephewKP. 2005. Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid, 15:551–561.
9.
ReyaT, CleversH. 2005. Wnt signalling in stem cells and cancer. Nature, 434:843–850.
10.
TetsuO, McCormickF. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398:422–426.
11.
HeTC, SparksAB, RagoC, HermekingH, ZawelL, da CostaLT, MorinPJ, VogelsteinB, KinzlerKW. 1998. Identification of c-MYC as a target of the APC pathway. Science, 281:1509–1512.
12.
TakahashiM, TsunodaT, SeikiM, NakamuraY, FurukawaY. 2002. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene, 21:5861–5867.
13.
IshigakiK, NambaH, NakashimaM, NakayamaT, MitsutakeN, HayashiT, MaedaS, IchinoseM, KanematsuT, YamashitaS. 2002. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab, 87:3433–3440.
14.
WeinbergerPM, AdamB-L, GourinCG, MoretzWH, BollagRJ, WangBY, LiuZ, LeeJR, TerrisDJ. 2007. Association of nuclear, cytoplasmic expression of galectin-3 with β-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg, 33:503–510.
15.
RezkS, BrynesRK, NelsonV, TheinM, PatwardhanN, FischerA, KhanA. 2004. Beta-catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol, 15:329–337.
16.
NakashimaM, MeirmanovS, NarukeY, KondoH, SaenkoV, RogounovitchT, Shimizu-YoshidaY, TakamuraN, NambaH, ItoM, AbrosimovA, LushnikovE, RoumiantsevP, TsybA, YamashitaS, SekineI. 2004. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant β-catenin expression. J Pathol, 202:446–455.
17.
WisemanSM, MasoudiH, NiblockP, TurbinD, RajputA, HayJ, FilipenkoD, HuntsmanD, GilksB. 2006. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg, 191:581–587.
18.
MahmoudNN, BoolbolSK, BilinskiRT, MartucciC, ChadburnA, BertagnolliMM. 1997. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res, 57:5045–5050.
19.
MahmoudNN, DannenbergAJ, MestreJ, BilinskiRT, ChurchillMR, MartucciC, NewmarkH, BertagnolliMM. 1998. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery, 124:225–231.
20.
RicePL, KelloffJ, SullivanH, DriggersLJ, BeardKS, KuwadaS, PiazzaG, AhnenDJ. 2003. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther, 2:885–892.
21.
BaronJA, ColeBF, SandlerRS, HaileRW, AhnenD, BresalierR, McKeown-EyssenG, SummersRW, RothsteinR, BurkeCA, SnoverDC, ChurchTR, AllenJI, BeachM, BeckGJ, BondJH, ByersT, GreenbergER, MandelJS, MarconN, MottLA, PearsonL, SaibilF, van StolkRU. 2003. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med, 348:891–899.
22.
ArberN, EagleCJ, SpicakJ, RaczI, DiteP, HajerJ, ZavoralM, LechugaMJ, GerlettiP, TangJ, RosensteinRB, MacdonaldK, BhadraP, FowlerR, WittesJ, ZauberAG, SolomonSD, LevinB. 2006. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med, 355:885–895.
23.
SteinbachG, LynchPM, PhillipsRK, WallaceMH, HawkE, GordonGB, WakabayashiN, SaundersB, ShenY, FujimuraT, SuLK, LevinB. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342:1946–1952.
WangJ, KnaufJA, BasuS, PuxedduE, KurodaH, SantoroM, FuscoA, FaginJA. 2003. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol, 17:1425–1436.
26.
MitsutakeN, KnaufJA, MitsutakeS, MesaCJr., ZhangL, FaginJA. 2005. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res, 65:2465–2473.
27.
AhmadM, ShiY. 2000. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene, 19:3363–3371.
28.
RaoAS, KremenevskajaN, von WasielewskiR, JakubcakovaV, KantS, ReschJ, BrabantG. 2006. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab, 91:159–168.
29.
De NigrisF, CeruttiJ, MorelliC, CalifanoD, ChiariottiL, VigliettoG, SantelliG, FuscoA. 2002. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer, 86:917–923.
30.
LinCI, WhangEE, AbramsonMA, DonnerDB, BertagnolliMM, MooreFDJr., RuanDT. 2009. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun, 379:626–631.
31.
GujralTS, van VeelenW, RichardsonDS, MyersSM, MeensJA, ActonDS, DunachM, ElliottBE, HoppenerJW, MulliganLM. 2008. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res, 68:1338–1346.
32.
CastelloneMD, De FalcoV, RaoDM, BellelliR, MuthuM, BasoloF, FuscoA, GutkindJS, SantoroM. 2009. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res, 69:1867–1876.
33.
CassinelliG, FaviniE, Degl'InnocentiD, SalviA, De PetroG, PierottiMA, ZuninoF, BorrelloMG, LanziC. 2009. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and β-catenin nuclear translocation. Neoplasia, 11:10–21.
34.
ZatelliMC, LuchinA, PiccinD, TagliatiF, BottoniA, VignaliC, BondanelliM, degli UbertiEC. 2005. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permability glycoprotein-mediated mechanism. J Clin Endocrinol Metab, 90:5754–5760.
35.
KnaufJA, MaX, SmithEP, ZhangL, MitsutakeN, LiaoXH, RefetoffS, NikiforovYE, FaginJA. 2005. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res, 65:4238–4245.
36.
MesaCJr., MirzaM, MitsutakeN, SartorM, MedvedovicM, TomlinsonC, KnaufJA, WeberGF, FaginJA. 2006. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res, 66:6521–6529.
37.
KebebewE, WengJ, BauerJ, RanvierG, ClarkOH, DuhQY, ShibruD, BastianB, GriffinA. 2007. The prevalence, prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 246:466–470discussion 470–471.
38.
NambaH, NakashimaM, HayashiT, HayashidaN, MaedaS, RogounovitchTI, OhtsuruA, SaenkoVA, KanematsuT, YamashitaS. 2003. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 88:4393–4397.
39.
NikiforovaMN, KimuraET, GandhiM, BiddingerPW, KnaufJA, BasoloF, ZhuZ, GianniniR, SalvatoreG, FuscoA, SantoroM, FaginJA, NikiforovYE. 2003. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 88:5399–5404.
40.
CastelloneMD, TeramotoH, WilliamsBO, DrueyKM, GutkindJS. 2005. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310:1504–1510.
41.
MrozekE, KloosRT, RingelMD, KrestyL, SniderP, ArbogastD, KiesM, MundenR, BusaidyN, KleinMJ, ShermanSI, ShahMH. 2006. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab, 91:2201–2204.
